Associated tags: Suicide, Depression, DSM-IV codes, NMDA, Post-traumatic stress disorder, Patient, Breakthrough, Ketamine, Therapy, FDA, PTSD, Food, Pharmaceutical industry, Dark Enlightenment, Breakthrough therapy, Lilly, Health, Letter, COVID-19, Novartis, Pfizer, US Foods, MPH, Fast Track, ASPE, National Security Advisor (United States), United States Army, JD, Biotechnology
Locations: DELAWARE, CALIFORNIA, UNION SQUARE, VIRGINIA, IV, PENNSYLVANIA
RADNOR, Pa., March 26, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its fourth quarter and full year 2023 financial results after the market closes on Thursday, March 28, 2024, via press release, which will be available on the Company's website at https://ir.nrxpharma.com/press-releases .
Key Points:
- RADNOR, Pa., March 26, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its fourth quarter and full year 2023 financial results after the market closes on Thursday, March 28, 2024, via press release, which will be available on the Company's website at https://ir.nrxpharma.com/press-releases .
- Due to scheduling conflicts and the Good Friday stock market holiday, the Company will now host its conference call to discuss the financial results as well as provide a corporate update on Monday, April 1, 2024, at 8:30 a.m.
- A live webcast of the conference call will be available on the Company's website at https://ir.nrxpharma.com/events .
- Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically +1-877-704-4453 or internationally +1-201-389-0920.
Suicide,
Depression,
Conference,
HOPE,
Science,
NMDA,
Patient,
CNS,
Efficacy,
Therapy,
Risk,
Neurotoxicity,
Spectrum,
PTSD,
Pharmaceutical industry RADNOR, Pa., March 25, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt, Chairman and Chief Scientist of NRx Pharmaceuticals and co-CEO of HOPE Therapeutics, will present at the Ketamine 2024 Conference, which is planned for March 25-27, 2024, at the Blavatnik School of Government in Oxford, UK.
Key Points:
- RADNOR, Pa., March 25, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt, Chairman and Chief Scientist of NRx Pharmaceuticals and co-CEO of HOPE Therapeutics, will present at the Ketamine 2024 Conference, which is planned for March 25-27, 2024, at the Blavatnik School of Government in Oxford, UK.
- The Ketamine 2024 Conference assembles many of the top scientists and clinicians in the field from around the world and is a forum for top researchers and experienced and interested clinicians to learn from each other about the therapeutic use of Ketamine and related compounds for affective disorders.
- Dr. Javitt will present a keynote talk titled, "Ketamine: the Efficacy is Clear, Approval is Critical, and the Risks Must be Balanced."
- "HOPE Therapeutics builds upon four decades of scientific discovery related to the role of the brain's NMDA receptor and the effects of ketamine and other NMDA-antagonist drugs in rapidly attenuating symptoms of depression and suicidality.
RADNOR, Pa., March 21, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its fourth quarter and full year 2023 financial results after the market closes on Thursday, March 28, 2024, via press release, which will be available on the Company's website at https://ir.nrxpharma.com/press-releases .
Key Points:
- RADNOR, Pa., March 21, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its fourth quarter and full year 2023 financial results after the market closes on Thursday, March 28, 2024, via press release, which will be available on the Company's website at https://ir.nrxpharma.com/press-releases .
- The Company will host a conference call to discuss the financial results as well as provide a corporate update at 4:30 p.m.
- A live webcast of the conference call will be available on the Company's website at https://ir.nrxpharma.com/events .
- Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically 1-877-704-4453, Int'l Investors Dial 1-201-389-0920.
The intent of the Board is to distribute 49% of HOPE stock in this dividend.
Key Points:
- The intent of the Board is to distribute 49% of HOPE stock in this dividend.
- Shares of HOPE are planned to be publicly listed
"This Dividend is another important step to building value for all of the Company's stakeholders.
- "As we build HOPE into a thriving, publicly-traded Specialty Pharmaceutical company we look forward to continuing to reward our investors."
- HOPE will additionally focus on digital therapeutics and other technologies to extend the pharmacologic effect of ketamine.
Organization,
HOPE,
Partnership,
Patient,
Sale,
NDA,
Detail,
Therapy,
Pharmacy,
FDA,
PTSD,
Pharmaceutical industry These are important steps to providing a full suite of ketamine options for customers across the country, and preparation for potential approval of HTX-100 by regulatory authorities worldwide.
Key Points:
- These are important steps to providing a full suite of ketamine options for customers across the country, and preparation for potential approval of HTX-100 by regulatory authorities worldwide.
- The Company has further entered into a business relationship with an organization that currently serves the business needs of more than 100 ketamine clinics nationwide.
- The Company has been given a target delivery date prior to the end of this month (March 2024) for initial stock of ketamine for sale to licensed end users.
- Details for ordering will be available on our website as soon as they are available.
Retrieved on:
Monday, February 26, 2024
Pharmacy,
HOPE,
Ketamine,
BIO,
Conference,
Marriott Marquis,
Therapy,
Patient,
Dark Enlightenment,
KEY,
Partnership RADNOR, Pa., Feb. 26, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals," the "Company"), a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt, Chairman and Chief Scientist of NRx Pharmaceuticals, will present a corporate overview at the BIO CEO & Investor Conference, which is scheduled to take place February 26-27, 2024, at the Marriott Marquis in New York City. Presenting with him will be Matthew Duffy, the newly-appointed co-CEO of HOPE Therapeutics. The presentation will be available on the NRx Pharmaceuticals website at https://www.nrxpharma.com/hope-therapeutics/.
Key Points:
- Presenting with him will be Matthew Duffy, the newly-appointed co-CEO of HOPE Therapeutics.
- The presentation will be available on the NRx Pharmaceuticals website at https://www.nrxpharma.com/hope-therapeutics/ .
- Additionally, we will be updating investors with regard to our plans to add a digital therapeutic component to our ketamine offering that has potential to extend the clinical benefit to patients."
- "We thank our investors for their support and look forward to updating the public on our progress towards building a lifesaving therapy."
Lotus notes that NRx has "achieved a significant milestone by completing enrollment for its phase 2b/3 trial of NRX-101 in suicidal treatment-resistant bipolar depression.
Key Points:
- Lotus notes that NRx has "achieved a significant milestone by completing enrollment for its phase 2b/3 trial of NRX-101 in suicidal treatment-resistant bipolar depression.
- Lotus further reported revenues of NT$1996, a 45% month over month increase.
- RADNOR, Pa., Feb. 9, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that its Asia Pacific strategic partner Lotus Pharmaceutical Co. Ltd (1975.TW) identified enrollment completion of the NRx clinical trial in bipolar depression as a material event in is February 7 financial filing.
- "We at NRx are honored that Lotus has focused its resources on helping us advance NRX-101 for the benefit of patients in the Asia Pacific region.
HOPE,
Therapy,
Patient,
New Drug Application,
FDA,
Ketamine,
Dark Enlightenment,
NDA,
ECT,
Suicide,
Electroconvulsive therapy,
Insurance,
DSM-IV codes,
Pharmaceutical industry This is designed with counsel to not be a taxable event for shareholders.
Key Points:
- This is designed with counsel to not be a taxable event for shareholders.
- "Incorporating HOPE Therapeutics is another important step in building value for NRx shareholders.
- HOPE is dedicated to providing an FDA-approved presentation of IV Ketamine, manufactured to current federal standards, in a diversion- and abuse-deterrent presentation.
- NRx also expects to convene a shareholder meeting in the coming weeks to vote on the planned structure of the spin-out of Hope Therapeutics and the stock dividend.
ECT,
Partnership,
Drug development,
Plasma protein binding,
FDA,
European,
Therapy,
REMS,
Keynote,
Dark Enlightenment,
MPH,
Mitigation,
Pharmaceutical industry "Ketamine's efficacy was so dramatic that ketamine became a standard of care ahead of the large clinical trials required for drug approval.
Key Points:
- "Ketamine's efficacy was so dramatic that ketamine became a standard of care ahead of the large clinical trials required for drug approval.
- Ketamine, as expected, now been demonstrated to be dramatically superior to placebo in large clinical trials.
- What could not be predicted is that ketamine has been shown to be at least as good as (i.e.
- We have partnered with Nephron Pharmaceuticals to develop a modern, single use, diversion- and tamper-resistant formulation of ketamine.
Retrieved on:
Wednesday, December 27, 2023
Nationally recognized attorney in highly regulated industries; healthcare specialist
Key Points:
- Nationally recognized attorney in highly regulated industries; healthcare specialist
RADNOR, Pa., Dec. 27, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company today announced that Janet Rehnquist has been elected to the Company's Board of Directors where she will chair the compliance and the nominating committees.
- Ms. Rehnquist is an experienced healthcare lawyer who specializes in reimbursement and compliance matters.
- "I am excited to join the Board of NRx Pharmaceuticals - a biotech company focused on developing drug treatments to address urgent unmet medical needs in CNS and mental health, particularly suicidal depression.
- "We at NRx are thrilled to welcome someone with Janet's distinguished record and unquestioned integrity to the Board of NRx Pharmaceuticals" said Jonathan Javitt, MD MPH, Founder and Chief Scientist of NRx Pharmaceuticals.
